Showing 20 of 24 recruiting trials for “chronic-myelomonocytic-leukemia”
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
👨⚕️ Leland Metheny, MD, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center📍 1 site📅 Started Feb 2025View details ↗
Oral-ATO for TP53-mutated Myeloid Malignancies
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
👨⚕️ Alexandra M Stevens, Pediatric Early Phase Clinical Trial Network📍 18 sites📅 Started Feb 2025View details ↗
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
👨⚕️ Uma M Borate, MD, Ohio State University Comprehensive Cancer Center📍 1 site📅 Started Aug 2024View details ↗
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
RecruitingNCT06111612 ↗
Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement
👨⚕️ Xianmin Song, MD, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine📍 1 site📅 Started Jan 2024View details ↗
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS
👨⚕️ John Pimanda, Professor, University of New South Wales📍 5 sites📅 Started Dec 2022View details ↗
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia
Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML
🏥 The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Mar 2022View details ↗
Study to Evaluate the Safety and Tolerability of EP0042
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
👨⚕️ Anna Halpern, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Mar 2020View details ↗
Combining Active and Passive DNA Hypomethylation
Page 1 of 2Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →